Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.73 +3.01%

+$0.81 today

Market cap
$1.81B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 5.16M

Average 1.81M

RARE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 100.6M shares rose 4.5% year over year, behind the +6.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +4.5% toward the trailing-twelve-month pace of +6.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.6M+0.7% QoQ
Last fiscal yearDec 2025
98.6M+8.9% YoY
LTMMar 2026
99.68M+6.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.5%——
1 year+8.9%——
3-year CAGR+12.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
98.6M USD
Year-over-year change
+8.9%
4-year CAGR
+9.8%

Weighted Avg Shares vs competitors

How RARE compares with its peers on the latest reported figures

  • RARE's LTM Mar 2026 weighted avg shares of 99.68M shares is the 5th highest of the 11 companies compared; the peer median is 81.46M shares.
  • Its year-over-year change of +6.6% is the 6th highest of 11, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of +12.1% compares with a peer median of +10.0%.
RARE Competitors Peer median
Weighted Avg Shares for RARE and competitors
Company Period LTM YoY 3-year CAGR
BBIOBridgeBio Pharma, Inc.LTM Jun 2026194.58M +2.6%+10.2%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026192.71M +0.7%+1.2%
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
ABEOAbeona Therapeutics Inc.LTM Mar 202654.09M +20.9%+88.9%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
Peer median (excluding RARE) 81.46M+6.8%+10.0%

Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.41M363.33M434.25M560.23M673M
Cost of Revenue16.01M28.32M45.21M76.73M109M
Gross Profit335.4M335.01M389.04M483.5M564M
Gross Margin95.4%92.2%89.6%86.3%83.8%
Research & Development497.15M705.79M648.45M697.87M750M
Selling, General & Admin219.98M278.14M309.8M321.61M349M
Operating Expenses717.14M983.93M958.25M1.02B1.1B
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
EBITDA(410.32M)(640.49M)(516.45M)(469M)(474M)
EBITDA Margin-116.8%-176.3%-118.9%-83.7%-70.4%
Operating Income(381.74M)(648.92M)(569.21M)(535.97M)(535M)
Operating Margin-108.6%-178.6%-131.1%-95.7%-79.5%
Interest Income1.93M11.07M26.69M36.51M25M
Interest Expense29.42M43.02M66M63.04M62M
Other Income / Expenses(71.24M)(52.81M)(39.26M)(31.61M)(36M)
Income Before Tax(452.98M)(701.73M)(608.46M)(567.59M)(571M)
Pre-Tax Margin-128.9%-193.1%-140.1%-101.3%-84.8%
Income Tax Expense1.04M5.7M(1.83M)1.6M4M
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Net Margin-129.2%-194.7%-139.7%-101.6%-85.4%
EPS (Basic)(6.70)(10.12)(8.25)(6.29)(5.83)
EPS (Diluted)(6.70)(10.12)(8.25)(6.29)(5.83)
Weighted Avg Shares67.8M69.91M73.54M90.54M98.6M
Weighted Avg Shares (Diluted)67.8M69.91M73.54M90.54M98.6M

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.